Safety Reading Notes

Read safety context beside the research guide.

The Liver enzymes and hepatotoxicity source set includes safety-context rows around Safety, adverse events, impairment, and formulation concerns. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 25999668

Early human research summary: mechanistic or pharmacological (1), preliminary human (1)

PubMed For Dummies Article

Liver enzymes and hepatotoxicity Evidence Review: the long-form source walk-through

Quick read
  • Liver enzymes and hepatotoxicity currently has 17 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 25999668
  • The evidence classes most visible in the row language are mechanistic or pharmacological (8), preliminary human (5), and insufficient (4). PMID 42057192
  • The study-design language most visible in the row language is Human clinical study (6), Cellular or in vitro study (4), Narrative or expert review (2), and other mapped categories (2). PMID 39004335
  • The repeated topics are endocannabinoid enzyme activity or metabolic mechanisms (12), safety, adverse-event, impairment, or formulation-specific concerns (2), safety, tolerability, sedation, adverse-event, impairment, or formulation-spe... (1), safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe... (1), and other mapped categories (1), which tells the reader where to start opening PubMed and DOI links. PMID 37458709

Start with the research question

Liver enzymes and hepatotoxicity is built from 17 source-backed evidence row(s) and 15 research source(s). The current evidence classes read as mechanistic or pharmacological (8), preliminary human (5), and insufficient (4), and the study-design language most often reads as Human clinical study (6), Cellular or in vitro study (4), Narrative or expert review (2), and other mapped categories (2). PMID 25999668

The row-level question is not simply whether Liver enzymes and hepatotoxicity is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are endocannabinoid enzyme activity or metabolic mechanisms (12), safety, adverse-event, impairment, or formulation-specific concerns (2), safety, tolerability, sedation, adverse-event, impairment, or formulation-spe... (1), safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe... (1), and other mapped categories (1). PMID 42057192

Human evidence 3 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 39630203

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 29768152

Mechanistic evidence 6 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 40622698

Limits and uncertainty 8 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 33022751

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 34918948

Where this page has the most source density

The largest bucket surfaced for this page is endocannabinoid enzyme activity or metabolic mechanisms. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is Safety, adverse events, impairment, and formulation concerns, which gives readers another way to see what the literature repeatedly circles. PMID 25999668

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 42057192

Bucket chapters: what the literature is circling

endocannabinoid enzyme activity or metabolic mechanisms

12 research sources 12 rows (224-373) Developed but mixed human research summary: insufficient (4), mechanistic or pharmacological (5), preliminary human (3)

Liver enzymes and hepatotoxicity appears in rows about endocannabinoid enzyme activity or metabolic mechanisms mechanisms. It currently draws from 12 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 25999668

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 25999668

  • Evidence row 224

    CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid en... PMID 25999668

  • Evidence row 373

    CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 39228144

Safety, adverse events, impairment, and formulation concerns

2 research sources 2 rows (163-164) Early human research summary: mechanistic or pharmacological (1), preliminary human (1)

Liver enzymes and hepatotoxicity appears in rows studying Safety, adverse events, impairment, and formulation concerns. It currently draws from 2 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 42057192

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 42057192

  • Evidence row 163

    CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: safety, adverse-event, impa... PMID 42057192

  • Evidence row 164

    CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vi... PMID 39004335

Safety, tolerability, adverse events, impairment, toxicity, and formulation concerns

1 research source 637 Early human research summary: preliminary human (1)

Liver enzymes and hepatotoxicity appears in rows studying Safety, tolerability, adverse events, impairment, toxicity, and formulation concerns. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 42057192

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 42057192

  • Evidence row 637

    CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: saf... PMID 42057192

safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns

1 research source 511 Mechanistic research summary: mechanistic or pharmacological (1)

Liver enzymes and hepatotoxicity appears in rows studying safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 39004335

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 39004335

  • Evidence row 511

    CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study d... PMID 39004335

TRPV4

1 research source 1023 Mechanistic research summary: mechanistic or pharmacological (1)

Liver enzymes and hepatotoxicity appears in rows about TRPV4 mechanisms. It currently draws from 1 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 38750093

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 38750093

  • Evidence row 1023

    Endocannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Human clinical study; outcome measure: TRPV4 channel activity, binding, signaling, or... PMID 38750093

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (3 row(s)), mechanistic evidence (6 row(s)), and safety/tolerability context (4 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 25999668

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 42057192

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 40750820
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 40774642
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 36912195

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 25999668

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 42057192

Source-reading checklist for Liver enzymes and hepatotoxicity

  1. Open the linked PubMed or DOI record. PMID 38904421
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 39228144
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 38750093
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 25999668
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 42057192

Source Notes

Liver enzymes and hepatotoxicity source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 163

    CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 42057192

    Evidence class: preliminary human. Source: Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract.
  2. Evidence row 164

    CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 39004335

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids.
  3. Evidence row 224

    CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 25999668

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiol rescues acute hepatic toxicity and seizure induced by cocaine.
  4. Evidence row 225

    CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 37458709

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Assessing Liver Effects of Cannabidiol and Valproate Alone and in Combination Using Quantitative Systems Toxicology.
  5. Evidence row 226

    CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 39630203

    Evidence class: insufficient; Study design: Human clinical study. Source: Short-term repeated oral intake of low dose cannabidiol: effects on liver enzyme activity and creatinine concentration during intense exercise.
  6. Evidence row 365

    CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 29768152

    Evidence class: preliminary human; Study design: Human clinical study. Source: Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
  7. Evidence row 366

    CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 40622698

    Evidence class: preliminary human; Study design: Human clinical study. Source: Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial.
  8. Evidence row 367

    CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 33022751

    Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial.
  9. Evidence row 368

    CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 34918948

    Evidence class: preliminary human. Source: Observed Impact of Long-Term Consumption of Oral Cannabidiol on Liver Function in Healthy Adults.
  10. Evidence row 369

    CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 40750820

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Hepatotoxicity evaluation of cannabidiol, cannabinol, cannabichromene and cannabigerol using a human quad culture liver chip.
  11. Evidence row 370

    CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 40774642

    Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Evaluating cannabidiol-induced liver injury with and without valproate using a three-dimensional human hepatocyte spheroid model.
  12. Evidence row 371

    CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 36912195

    Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis.
  13. Evidence row 372

    CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 38904421

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Metabolism and liver toxicity of cannabidiol.
  14. Evidence row 373

    CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 39228144

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Clinical guidance for cannabidiol-associated hepatotoxicity: A narrative review.
  15. Evidence row 511

    CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns). PMID 39004335

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids.
  16. Evidence row 637

    CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 42057192

    Evidence class: preliminary human. Source: Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract.
  17. Evidence row 1023

    Endocannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Human clinical study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 38750093

    Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Transcriptomic signature, bioactivity and safety of a non-hepatotoxic analgesic generating AM404 in the midbrain PAG region.